Immodulon Appoints New Chair and Leadership Team to Drive Late-Stage Clinical Development of IMM-101 in Pancreatic Cancer
10 mai 2023 03h00 HE
|
Immodulon
Richard Davies, Deputy Chairman of Alvotech, elected as Chairman of the BoardGertjan Bartlema, formerly at Celgene and Amgen, appointed as Chief Executive OfficerPeter Greaney, formerly at ADC...
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
04 mai 2023 16h05 HE
|
Immuneering Corporation
- Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program presented at American Association for Cancer Research (AACR) annual meeting - -First...
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
12 avr. 2023 16h05 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Community Oncology Services Global Market Report 2023: Government Investments in Oncology Bolsters $132.5 Billion Industry
07 avr. 2023 04h38 HE
|
Research and Markets
Dublin, April 07, 2023 (GLOBE NEWSWIRE) -- The "Community Oncology Services Global Market Opportunities And Strategies To 2032" report has been added to ResearchAndMarkets.com's offering.The...
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
05 avr. 2023 08h00 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher
29 mars 2023 09h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, March 29, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the “Company”) announces that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy...
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast
27 mars 2023 09h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
06 mars 2023 16h05 HE
|
Immuneering Corporation
First patient dosed in Phase 1/2a clinical trial of IMM-1-104 in advanced solid tumors with any RAS mutation Provides debut guidance for IMM-1-104 program: initial Phase 1 PK and safety data expected...
AIM ImmunoTech Issues Letter to Stockholders
06 mars 2023 08h45 HE
|
AIM ImmunoTech Inc.
Year marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity with the investment and...
SiSaf and the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer
02 mars 2023 04h00 HE
|
SiSaf Ltd
GUILDFORD, United Kingdom, March 02, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd today announces its collaboration with the University of Leipzig, Germany, to develop...